Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
A patient with metastatic pancreatic cancer, ECOG performance status 2, and pre-existing neuropathy faces sequential treatment decisions. This interactive case examines tolerability, molecular findings, and safety counseling without implying that every detected alteration is actionable.
Medical Oncology November 11th 2026
Cancer Therapy Advisor
In DeLLphi-305, median overall survival was 21.1 months with tarlatamab plus durvalumab versus 12.7 months with durvalumab alone after first-line chemoimmunotherapy. Cytokine release syndrome occurred in approximately half of patients receiving the combination.
Medical Xpress
Analysis of 189 colorectal tumors linked younger age to differences in stromal composition and gene activity. Additional datasets supported the stromal finding, but the study did not establish that these patterns cause aggressive disease.
Gastroenterology November 11th 2026
Oncology News Central (ONC)
In SAFFRON, median overall survival reached 17.8 months with dual EGFR/MET inhibition versus 12.9 months with chemotherapy. Results apply to patients with MET overexpression and/or amplification after osimertinib progression, not all EGFR-mutated NSCLC.
Clinical Advances in Hematology & Oncology
Prior immunotherapy exposure, recurrence timing, and toxicity shape treatment choices in clear cell renal cell carcinoma. An expert review examines sequencing across adjuvant and metastatic settings, while identifying gaps in prospective evidence after adjuvant treatment.
News Medical
Radiation shifted protective innate lymphoid cells toward an inflammatory state in preclinical experiments. Disrupting interferon signaling reduced lung injury and fibrosis in mice, but the study did not establish benefit in patients.